Tatva Chintan Pharma Chem Limited Share Price

Equities

TATVA

INE0GK401011

Specialty Chemicals

End-of-day quote NSE India S.E. 03:30:00 31/05/2024 am IST 5-day change 1st Jan Change
1,034 INR -4.53% Intraday chart for Tatva Chintan Pharma Chem Limited -5.79% -35.46%
Sales 2024 393.5Cr 4.72Cr Sales 2025 * 519.2Cr 6.22Cr Capitalization 2.42TCr 29Cr
Net income 2024 30Cr 36.45L Net income 2025 * 51Cr 61.5L EV / Sales 2024 6.41 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 4.66 x
P/E ratio 2024
81.3 x
P/E ratio 2025 *
47.2 x
Employees 608
Yield 2024 *
0.15%
Yield 2025 *
0.33%
Free-Float 27.98%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Tatva Chintan Pharma Chem Limited, Q4 2024 Earnings Call, May 03, 2024
Tatva Chintan Pharma Chem Limited Recommends Final Dividend for the Financial Year 2023-2024 CI
Tatva Chintan Pharma Chem Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Tatva Chintan Pharma Chem Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Tatva Chintan Pharma Chem Limited Accords Environmental Clearance to for Setting Up Plant for Manufacturing of Chemicals CI
Certain Equity Shares of Tatva Chintan Pharma Chem Limited are subject to a Lock-Up Agreement Ending on 25-FEB-2024. CI
Transcript : Tatva Chintan Pharma Chem Limited, Q3 2024 Earnings Call, Jan 20, 2024
Tatva Chintan Pharma Chem Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Transcript : Tatva Chintan Pharma Chem Limited, Q2 2024 Earnings Call, Nov 02, 2023
Tatva Chintan Pharma Chem Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Crisil Affirms A- Rating on Tatva Chintan Pharma Chem's Debt Financing; Outlook Stable MT
Transcript : Tatva Chintan Pharma Chem Limited, Q1 2024 Earnings Call, Aug 04, 2023
Tatva Chintan Pharma Chem Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Tatva Chintan Pharma Chem's Consolidated Profit Shrinks in Fiscal Q4 MT
Transcript : Tatva Chintan Pharma Chem Limited, Q4 2023 Earnings Call, May 05, 2023
More news
1 day-4.53%
1 week-5.79%
1 month-15.83%
3 months-14.90%
6 months-31.44%
Current year-35.46%
More quotes
1 week
1 030.00
Extreme 1030
1 096.00
1 month
1 030.00
Extreme 1030
1 283.70
Current year
1 030.00
Extreme 1030
1 612.10
1 year
1 030.00
Extreme 1030
1 887.95
3 years
1 030.00
Extreme 1030
2 977.80
5 years
1 030.00
Extreme 1030
2 977.80
10 years
1 030.00
Extreme 1030
2 977.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 12/96/12
Director of Finance/CFO - 03/21/03
Chief Administrative Officer - 21/15/21
Members of the board TitleAgeSince
Director/Board Member 64 27/21/27
Chief Executive Officer 51 12/96/12
Director/Board Member 52 12/96/12
More insiders
Date Price Change Volume
31/24/31 1,034 -4.53% 209,193
30/24/30 1,083 +0.81% 16,339
29/24/29 1,074 -0.23% 30,265
28/24/28 1,076 +0.30% 20,816
27/24/27 1,073 -2.19% 39,411

End-of-day quote NSE India S.E., May 31, 2024

More quotes
Tatva Chintan Pharma Chem Limited is an India-based specialty chemical manufacturing company. The Company is engaged in the manufacturing of verity of chemicals include structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for capacitor batteries, and pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC). Its SDAs are quarternary salts, which helps in the formation of channels and pores during the synthesis of zeolites. Its PTCs are used to facilitate the migration of a reactant from one phase into another phase where the reaction occurs in a heterogeneous multi-phase system. The Company operates two manufacturing facilities situated at Ankleshwar and Dahej in Bharuch, Gujarat, India. The Company is focused on serving various customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavors and fragrances industries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1,034 INR
Average target price
1,674 INR
Spread / Average Target
+61.96%
Consensus